Cantor Fitzgerald
Cantor Fitzgerald is a privately held New York investment bank and brokerage controlled by the Lutnick family. Its equity research covers more than 500 companies, concentrated in healthcare and technology.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 53912M
- Actions
- 2,19712M
- Ratings / Price targets
- 1,267 / 930
- Upgrades / Downgrades
- 29 / 32
- Initiations
- 48
- Buy-rated
- 74%of 482 rated
- Median upside
- +19.7%
- Targets raised / lowered
- 415 / 249
- On record
- Feb 2012 – Sep 2026
Overview
Cantor's equity research covers more than 500 companies across healthcare, technology, financials and industrials as of 2026, with teams in biotechnology, healthcare services, large-cap biopharma, medical devices, software, semiconductors, fintech, crypto mining and blockchain, industrial technology and metals and mining. As of 2026, Cantor says it offers weekly webinars and pairs coverage with non-deal roadshows and sector conferences.
Bernard Gerald Cantor and John Fitzgerald founded the firm in 1945; in 1972 it became the first electronic marketplace for U.S. government securities. Howard Lutnick was named chief executive in 1991 and rebuilt the firm after the September 11, 2001 attacks killed 658 employees at its World Trade Center offices. It spun off BGC Partners in 2004. In 2025 Lutnick became U.S. Commerce Secretary; his son Brandon became chairman and three co-chief executives took over Cantor Fitzgerald & Co.
Milestones
- 1945
Founded by Bernard Gerald Cantor and John Fitzgerald
- 1972
Launched first electronic marketplace for U.S. government securities
- 1991
Howard Lutnick named president and chief executive
- 2001
Lost 658 employees in the September 11 attacks
- 2004
Spun off voice brokerage business as BGC Partners
- 2025
Brandon Lutnick named chairman as Howard Lutnick joined government
Firm facts
- Legal name
- Cantor Fitzgerald, L.P.
- Type
- Full-service
- Founded
- 1945
- Headquarters
- New York, United States
- Co-Chief Executive Officer and Global Head of Equities, Cantor Fitzgerald & Co.
- Pascal Bandelier
- Rating scale
- OverweightNeutralUnderweight12 months
- Website
- cantor.com
Research philosophy
We don’t want to be the 25th or 30th analyst on a name.
When Cantor expanded its equity research in 2012, it was still best known for bonds. Its research director said the team would focus on small- and mid-cap stocks that received limited analyst attention or had fallen out of favor with investors. As of 2026, Cantor says its research combines proprietary models, detailed analysis and interviews with leading industry experts.
Rating methodology
Ratings are absolute: Overweight for an expected 12-month total return above 15%, Neutral for −10% to 15%, and Underweight below −10%.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Tesla, Inc.TSLA | Overweight | $485 |
 Amazon.com, Inc.AMZN | Overweight | $320 |
 Applied Materials, Inc.AMAT | Overweight | $850 |
 NVIDIA CorporationNVDA | Overweight | $350 |
 Booking Holdings Inc.BKNG | Neutral | $220 |
 CrowdStrike Holdings, Inc.CRWD | Overweight | $250 |
 Alphabet Inc.GOOGL | Overweight | $420 |
 Texas Instruments IncorporatedTXN | Neutral | $340 |
 Western Digital CorporationWDC | Overweight | $900 |
 KLA CorporationKLAC | Overweight | $325 |
Most active analysts
- Deepak Mathivanan67 notesBKNGAMZNETSY
- Thomas Blakey43 notesTEAMSNOWESTC
- Richard Anderson38 notesEGPCSRSBRA
- Brett Knoblauch36 notesCLSKHIVEMARA
- Jonathan Ruykhaver33 notesSOKTACRWD
- Ramsey El-Assal30 notesAFRMBETRXYZ
Recent actions
| Date | Stock | Rating action | Rating | Target | Analyst |
|---|---|---|---|---|---|
| Sep 22 | IDIDEAYA Biosciences, Inc.IDYA | Reiterate | Overweight | ||
| Sep 22 | FOFormFactor, Inc.FORM | Reiterate | Overweight | ||
| Sep 22 |  Camtek Ltd.CAMT | Reiterate | Neutral | $120 →$175 | Matthew Prisco |
| Sep 22 | AEAdvanced Energy Industries, Inc.AEIS | Reiterate | Overweight | ||
| Sep 22 | AVAvePoint, Inc.AVPT | Reiterate | Overweight | ||
| Sep 22 | PTPTC Therapeutics, Inc.PTCT | Target | $130 →$137 | Kristen Kluska | |
| Sep 22 |  Summit Therapeutics Inc.SMMT | Reiterate | Overweight | ||
| Sep 22 | AVArriVent BioPharma, Inc. Common StockAVBP | Reiterate | Overweight | ||
| Sep 22 |  Merck & Co., Inc.MRK | Reiterate | Neutral | ||
| Sep 22 | ANAnaptysBio, Inc.ANAB | Reiterate | Overweight | ||
| Sep 22 | LPLipocine Inc.LPCN | Reiterate | Overweight |